

Regdanvimab

Cat. No.:	HY-P99346
CAS No.:	2444308-95-4
Target:	SARS-CoV; Angiotensin-converting Enzyme (ACE)
Pathway:	Anti-infection; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 ^[1] .	
IC₅₀ & Target	SARS-CoV-2, ACE2 ^[1]	
In Vitro	Regdanvimab (CT-P59) (0-1000 ng/mL; 72 h) can neutralize Gamma, Delta and Epsilon variants with IC ₅₀ s of 161.5-1237 ng/mL ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Regdanvimab (CT-P59) (5-80 mg/kg; i.p.; single dose) has an ability to lower viral burden against Gamma and Delta variants in mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	hACE2 transgenic (TG) mice inoculated with Gamma or Delta variant ^[1]
	Dosage:	5, 20, 40, and 80 mg/kg
	Administration:	Intraperitoneal injection, 8 h post-inoculation, single dose
	Result:	Delayed body weight loss and showed a statistically significant difference compared to the placebo group. Prevented the weight loss of the mice infected with Delta variant. Significantly inhibited the virus replication in the respiratory tract.

REFERENCES

[1]. Ryu DK, et al. The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. *Biochem Biophys Res Commun.* 2021 Nov 12;578:91-96.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA